Clinical Review

Treatment with five-alpha reductase inhibitors (5αRIs) does not appear to elevate the risk of hospitalization for heart failure (HF), myocardial infarction (MI), stroke, or cardiovascular death among men with benign prostatic hyperplasia (BPH), a study has shown.

Most men with a history of anabolic steroid use have severe oligospermia, with only a few of them achieving normal semen parameters after 6 months of treatment, according to a study.

Treatment with the oral form of nalbuphine, PHN131, appears to effectively control moderate-to-severe pain in patients who have undergone hemorrhoidectomy, according to a study.

In the treatment of Crohn’s disease (CD), the triple combination of vedolizumab, adalimumab, and methotrexate leads to endoscopic remission in 34.5 percent of patients and clinical remission in 54.5 percent, according to data from the phase IV EXPLORER trial.

Normal-tension glaucoma (NTG) patients with hypertension who experience morning blood pressure (BP) surge are likely to have visual field progression, as shown in a study.

Mefenamic acid shows no significant interaction with ciprofol in healthy individuals, which suggests that ciprofol is safe and well tolerated when administered along with mefenamic acid, reports a study.

The risk of herpes zoster (HZ) and HZ-related hospitalization is much higher among patients with liver cirrhosis (LC), especially those who are not currently recommended for HZ vaccination, than the general population, according to a nationwide population-based study in Korea.

Adding subablative stereotactic body radiotherapy (SBRT) concurrently to immune checkpoint inhibitor (ICI) monotherapy does little to improve survival outcomes in patients with advanced solid tumours, as shown in the phase II CHEERS trial.

In the treatment of select patients with rheumatoid arthritis (RA), otilimab is neither better than placebo nor noninferior to sarilumab in terms of the proportion of patients achieving an American College of Rheumatology ≥20 percent response (ACR20), according to the results of the phase III ContRAst 3 study.

Use of a chemometric approach appears helpful in the evaluation of interactions between antiretroviral medications and food, suggests a recent study.